QTRX

Quanterix Corp

A maker of ultra-sensitive blood tests and tissue-imaging tools for biology research and diagnostics. Its Simoa platform detects single protein molecules in blood, powering tests like LucentAD Complete for Alzheimer's disease, while its PhenoCycler spatial biology systems map proteins inside intact tissue. Founded in 2007 by scientist David Walt, whose lab invented the single-molecule array technology, the company began life as Digital Genomics before renaming itself Quanterix. Simoa is short for "single molecule array," and the firm grew further by acquiring spatial-biology pioneer Akoya Biosciences in 2025.

CUSIP: 74766Q101HealthcareUS1 holder

Ownership Activity Financials Filings

Insiders

Ranked by how much each holding moved in the last 5 years

Insider

Walt David RDirector · 16 transactions

1.87M+46.5%

Granted 29.2K · Bought 567.0K

Hrusovsky E KevinExecutive Chairman, Director · 29 transactions

910.2K-2.1%

as of Jul 2022

Granted 25.6K · Sold 44.0K

Toloue MasoudPresident & CEO, Director · 72 transactions

507.3K+900.6%

Granted 354.1K · Bought 169.9K · Sold 6.4K

Meister Paul MDirector · 24 transactions

313.3K+2193%

Granted 65.3K · Bought 234.3K

Madaus Martin DDirector · 7 transactions

291.5K—

as of Jan 2025

Granted 21.9K · Bought 89.7K

Donnelly William PExecutive Chair, Director · 16 transactions

154.1K—

Granted 43.6K · Bought 113.3K

Crandell KeithDirector · 15 transactions

131.2K+37%

as of Apr 2023

Granted 16.2K

Doyle Michael ACFO and Treasurer · 19 transactions

88.3K+1497.3%

as of Sep 2023

Granted 41.7K · Bought 30.0K · Sold 471

Hampton Malcolm GarretDirector · 2 transactions

70.1K—

Granted 70.1K

Sachs Alan BruceDirector · 2 transactions

70.1K—

Granted 70.1K

Hlavinka Sarah E.Director · 22 transactions

60.1K+415.2%

as of Jul 2025

Granted 38.3K · Bought 10.2K

Flynn KarenDirector · 8 transactions

57.2K—

Granted 57.2K

Lai Goldman MylaDirector · 5 transactions

54.8K—

Granted 54.8K

Duffy David C.SVP R&D and CTO · 10 transactions

54.7K+82.7%

as of Mar 2022

Granted 41.2K · Sold 16.5K

Magovcevic-Liebisch IvanaDirector · 3 transactions

43.6K—

Granted 43.6K

Elliott Jeffrey ThomasDirector · 3 transactions

42.8K—

Granted 42.8K

Fry John JGeneral Counsel & Secretary · 19 transactions

37.7K+11.8%

as of Aug 2022

Sold 5.1K

Mattoon DawnSr. VP, Diagnostics · 18 transactions

36.9K-1.8%

as of Apr 2022

Granted 10.7K · Sold 11.4K

Miller Michael FrancisChief Technology Officer · 48 transactions

33.9K—

Granted 6.7K

Sriram VandanaChief Financial Officer · 52 transactions

31.6K—

Granted 96.1K · Bought 4.2K

Roskey Mark T.SVP, Strategic Partnerships · 14 transactions

22.3K-6.4%

as of Apr 2022

Sold 1.5K

Blaser Brian JDirector · 2 transactions

19.0K—

as of Jan 2024

Granted 19.0K

Olson Laurie JDirector · 10 transactions

13.7K+202.6%

as of May 2024

Granted 15.7K · Sold 6.5K

Mendel ScottDirector · 6 transactions

12.5K—

Granted 60.4K

Meadows BenjaminChief Commercial Officer · 1 transaction

3.5K—

Bought 3.5K

Insider	Stake change	Holds now	Granted / vested	Bought	Sold
Walt David RDirector · 16 transactions	+46.5%	1.87M	29.2K	567.0K	—
Hrusovsky E KevinExecutive Chairman, Director · 29 transactions	-2.1%	910.2Kas of Jul 2022	25.6K	—	44.0K
Toloue MasoudPresident & CEO, Director · 72 transactions	+900.6%	507.3K	354.1K	169.9K	6.4K
Meister Paul MDirector · 24 transactions	+2193%	313.3K	65.3K	234.3K	—
Madaus Martin DDirector · 7 transactions	—	291.5Kas of Jan 2025	21.9K	89.7K	—
Donnelly William PExecutive Chair, Director · 16 transactions	—	154.1K	43.6K	113.3K	—
Crandell KeithDirector · 15 transactions	+37%	131.2Kas of Apr 2023	16.2K	—	—
Doyle Michael ACFO and Treasurer · 19 transactions	+1497.3%	88.3Kas of Sep 2023	41.7K	30.0K	471
Hampton Malcolm GarretDirector · 2 transactions	—	70.1K	70.1K	—	—
Sachs Alan BruceDirector · 2 transactions	—	70.1K	70.1K	—	—
Hlavinka Sarah E.Director · 22 transactions	+415.2%	60.1Kas of Jul 2025	38.3K	10.2K	—
Flynn KarenDirector · 8 transactions	—	57.2K	57.2K	—	—
Lai Goldman MylaDirector · 5 transactions	—	54.8K	54.8K	—	—
Duffy David C.SVP R&D and CTO · 10 transactions	+82.7%	54.7Kas of Mar 2022	41.2K	—	16.5K
Magovcevic-Liebisch IvanaDirector · 3 transactions	—	43.6K	43.6K	—	—
Elliott Jeffrey ThomasDirector · 3 transactions	—	42.8K	42.8K	—	—
Fry John JGeneral Counsel & Secretary · 19 transactions	+11.8%	37.7Kas of Aug 2022	—	—	5.1K
Mattoon DawnSr. VP, Diagnostics · 18 transactions	-1.8%	36.9Kas of Apr 2022	10.7K	—	11.4K
Miller Michael FrancisChief Technology Officer · 48 transactions	—	33.9K	6.7K	—	—
Sriram VandanaChief Financial Officer · 52 transactions	—	31.6K	96.1K	4.2K	—
Roskey Mark T.SVP, Strategic Partnerships · 14 transactions	-6.4%	22.3Kas of Apr 2022	—	—	1.5K
Blaser Brian JDirector · 2 transactions	—	19.0Kas of Jan 2024	19.0K	—	—
Olson Laurie JDirector · 10 transactions	+202.6%	13.7Kas of May 2024	15.7K	—	6.5K
Mendel ScottDirector · 6 transactions	—	12.5K	60.4K	—	—
Meadows BenjaminChief Commercial Officer · 1 transaction	—	3.5K	—	3.5K	—

Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.